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Edited by Irmgard SinningAbstract Evasion of apoptosis is recognized as a characteristic
of malignant growth. Anti-apoptotic B-cell lymphoma-2 (Bcl-2)
family members have therefore emerged as potential therapeutic
targets due to their critical role in proliferating cancer cells.
Here, we present the crystal structure of Bﬂ-1, the last anti-
apoptotic Bcl-2 family member to be structurally characterized,
in complex with a peptide corresponding to the BH3 region of the
pro-apoptotic protein Bim. The structure reveals distinct features
at the peptide-binding site, likely to deﬁne the binding speciﬁcity
for pro-apoptotic proteins. Superposition of the Bﬂ-1:Bim com-
plex with that of Mcl-1:Bim reveals a signiﬁcant local plasticity
of hydrophobic interactions contributed by the Bim peptide,
likely to be the basis for the multi speciﬁcity of Bim for anti-
apoptotic proteins.
 2008 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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Crystal structure1. Introduction
The B-cell lymphoma-2 (Bcl-2) protein family contains
both pro- and anti-apoptotic members that play critical
roles in the mitochondrial apoptotic pathways [1]. Cancer
cells frequently over-express anti-apoptotic Bcl-2 family
members that suppress apoptotic signals. Members of the
Bcl-2 family interact through their Bcl-2 homology (BH)
motifs [2,3]. Bax, Bak and Bok, share three BH motifs
(BH1, BH2 and BH3) and are proposed to induce perme-
abilization of the mitochondrial outer membrane, resulting
in cytochrome c release and the subsequent activation of
caspases [4]. The anti-apoptotic Bcl-2 family members,
Bcl-2, Bcl-xL, Bcl-w, Mcl-1 and Bﬂ-1, contain four BHAbbreviations: Bcl-2, B-cell lymphoma-2; BH, Bcl-2 homology motif
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doi:10.1016/j.febslet.2008.09.028motifs and a membrane-anchoring sequence at their C-ter-
minus [3]. The pro-apoptotic BH3-only proteins contain a
single BH motif.
While it is known that apoptosis is regulated by interac-
tions between the diﬀerent Bcl-2 family members, the exact
hierarchy of these interactions in diﬀerent cell contexts re-
mains controversial [5,6]. Some of the BH3-only proteins
(Bad, Bik, Hrk, Bmf and Noxa) most likely execute their
pro-apoptotic eﬀects by directly binding and inactivating
anti-apoptotic Bcl-2 proteins [7]. The BH3-only proteins
Bim, Bid and Puma could work in a similar fashion but
have been shown to also work as direct activators of Bak,
Bax and Bok [3]. The main function of the anti-apoptotic
Bcl-2 members would then be to sequester Bim, Bid and
Puma, thereby blocking their activation of Bax, Bak and
Bok. This scenario is in contrast to earlier proposal where
the anti-apoptotic members have been suggested to act and
interact directly on Bax, Bak and Bok [8]. In either case,
it is certain that BH3-only proteins function is to regulate
apoptosis by binding though the BH3 motif to its diﬀerent
partners.
Structural studies on several of the multi-BH motif Bcl-2
proteins have revealed a common fold constituted by two cen-
tral hydrophobic helices surrounded by six or seven amphi-
pathic helices [2,3]. The binding site for the BH3 regions of
pro-apoptotic BH3-only proteins is located at a hydrophobic
groove formed by the BH1, BH2 and BH3 motifs [9,10].
Structural studies of complexes between anti-apoptotic pro-
teins and BH3 peptides of pro-apoptotic BH3-only proteins
such as mouse Bcl-xl:Bim [11], human Bcl-xl:Bak [10], human
Bcl-w:Bid [12], mouse Mcl-1:NoxaB and of human Mcl-1:Bim
[13], have revealed insights into the speciﬁcity determinants for
BH3 interactions.
This paper presents the crystal structure of Bﬂ-1, the only
mammalian anti-apoptotic Bcl-2 family member lacking struc-
tural information, in complex with a BH3 peptide from Bim.
Bﬂ-1 confers protection against various apoptotic stimuli such
as activation of the TNF receptor, oxidative stress, over-
expression of Bax and Bid and chemotherapeutic treatments,
[14]. It has been demonstrated that Bﬂ-1 interacts with the
BH3-only proteins Bim, Bid, Puma and Noxa in vivo [5] and
in vitro [7,15]. The structure of Bﬂ-1 in complex with Bim pro-
vides new information of the structural basis for Bim recogni-
tion and can serve as a basis for deﬁning epitopes for the
design of anti-apoptotic inhibitors.ation of European Biochemical Societies.
Fig. 1. Overall structure. (A) The structure of Bﬂ-1 with Bim-BH3
peptide, where Bim peptide is colored in yellow and Bﬂ-1 in green with
motif BH1, BH2 and BH3 colored in magenta, blue and red,
respectively. (B) Superposition of the Bﬂ-1 structure (green) with that
of Mcl-1 (2PQK) (brown). The Bim peptide has been omitted from
both structures, for clarity.
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2.1. Protein production
Human Bﬂ-1 protein (residues 1–149), lacking the C-terminal 26 res-
idues, was expressed in Escherichia coli strain BL21 (DE3) using the
pET-based vector pNIC-Bsa4a (Novagen). The recombinant protein
contained an N-terminal 6 ·His-tag followed by a TEV-protease site.
Cell cultivation and protein expression were performed as described
previously [16]. Human Bim-BH3 peptide (DMRPEIWIAQELRRI-
GDEFNAYYAR), corresponing to residues 141–165, was synthesized
by GenScript Corporation, Scotch Plains USA. Cell extract prepara-
tion, puriﬁcation protocol and buﬀer compositions were as previously
described [16]. Final gel ﬁltration was performed in 20 mM HEPES,
300 mM NaCl, 10% glycerol, 2 mM TCEP, pH 7.5. The His-tag was
removed by TEV-protease treatment. The purity (>98%) of the protein
was estimated by SDS–PAGE (data not shown). Molecular weight
(19.7 kDa) and protein identity was veriﬁed by mass-spectrometry.
The protein was concentrated to 8 mg/ml, frozen in liquid nitrogen
and stored at 80 C until further handling. The same methods were
used for purifying selenomethionine-labeled protein used for MAD
phasing. Mass-spectrometry conﬁrmed the incorporation of three Se-
Met.
2.2. Crystallization and data collection
Bﬂ-1 protein was mixed with an equimolar amount of Bim-BH3 pep-
tide. The protein complex was crystallized in hanging drops containing
1 ll of protein solution (8 mg/ml) and 1 ll well solution (0.1 M BisTris
pH 5.8 and 1.8–2.0 M (NH4)2SO4), at 20 C. Crystals were harvested
into a cryo-protecting solution composed of the reservoir solution sup-
plemented with 25% glycerol and frozen in liquid nitrogen. Native and
MAD data sets were collected at European Synchrotron Ring Facility
(ESRF) at beam lines BM14.1 (2.2 A˚ resolution) and ID29 (2.5 A˚ res-
olution), respectively.
2.3. Structure solution and reﬁnement
Data sets were processed with XDS and scaled with XSCALE [17].
The structure of Bﬂ-1 was solved by MAD phasing using peak and
inﬂection point data sets (Table S1). SOLVE [18] located 2 of the 3
selenium sites in the asymmetric unit. RESOLVE [18] was used to car-
ry out solvent ﬂattening and subsequent initial model building. Molec-
ular replacement was done using MOLREP [19]. The model was
improved using ARP/wARP [20], and reﬁned in REFMAC5 [21].
Manual model building was done using Coot. Crystal data and reﬁne-
ment statistics are shown in Table S1. Structure analysis was aided by
Coot. Coordinates and structure factors for Bﬂ-1 were deposited to the
PDB with the accession code 2VM6.3. Results
3.1. Overall structure
The crystal structure of Bﬂ-1 was solved at 2.2 A˚ resolution
with one Bﬂ-1:Bim complex in the asymmetric unit. Bﬂ-1
shows a compact fold composed of eight a-helices, which con-
stitute the canonic Bcl-2 fold (Fig. 1A). All amino acids from
residues 1 to 149 was modeled into the electron density, except
for residues 25–30. This disordered stretch connects helices a1
and a2 – a region which diﬀers greatly in length between Bcl-2
family members, and which is usually disordered [2,3]. The
binding groove for the Bim peptide is composed of a cleft
formed between the a2, a3, a4, a5, a7 and a8 helices, that also
contains the BH1, BH2 and BH3 motifs. Some of the most
conserved residues in these motifs play structural roles while
others contribute directly to the peptide-binding pocket.
Although the overall sequence identity between Bﬂ-1 and other
anti-apoptotic members of the Bcl-2 family is relatively low,
ranging from 19% (Bcl-w) to 35% (Mcl-1) (Table S2), their
three-dimensional architectures are very similar. Root mean
square deviations are in the range of 3.2 A˚ (Bcl-w, 115residues) to 1.8 A˚ (Bcl-xl, 144 residues). The superposition of
human Bﬂ-1 with human Mcl-1 (2PQK) is shown in Fig. 1B.
The largest structural diﬀerences are seen in helices a2 and
a3 and the connecting region between helices a5 and a6. The
structural changes in these two regions are partially concerted
– helix a3, which line the Bim peptide-binding pocket, are
partially packing on top of the region where helices a5 and
a6 connect.
3.2. The Bﬂ-1:Bim interaction
The Bﬂ-1 Bim-BH3 peptide-binding pocket has similar
overall properties as the corresponding groove in other Bcl-2
proteins. Several hydrophobic patches line along the pocket
at positions conserved in the Bcl-2 proteins, and have been la-
beled h1–h4 (Fig. 2A). These hydrophobic patches interact
with highly conserved residues on the amphipathic helix of
BH3-only proteins (Fig. 2B). In the Bim peptide these residues
are represented by Ile148, Leu152, Ile155 and Phe159. The Bim
peptide makes two additional hydrophobic interactions;
Trp147 of Bim stacks onto a surface patch formed by Leu52
and Cys55 of Bﬂ-1, and Tyr163 of Bim makes hydrophobic
Fig. 2. Bﬂ-1:Bim interaction. (A) Comparison of the Bﬂ-1:Bim complex (left, Bim peptide is colored yellow) with the Mcl-1:Bim complex (right, Bim
peptide is colored blue). Black labels refers to Bim residues, white labels refers to Bﬂ-1. Bﬂ-1 and Mcl-1 are rendered as electrostatic potential surface
models. (B) Sequence alignment of BH3 motifs from diﬀerent BH3-only proteins. The conserved hydrophobic residues h1, h2, h3, h4 and h5 are
highlighted in yellow, red, light blue, green and pink, respectively. Figure prepared using the ESPript server [31]. (C) Close views on the interactions
of Trp147 and Tyr163 of Bim with the peptide-binding pocket of Bﬂ-1.
Fig. 3. Bim binding to human Bﬂ-1 and Mcl-1 induces diﬀerent side-
chain conformations in Bim. Shown is a ribbon representation of the
a2 and a3 helices and the Bim peptide from Bﬂ-1:Bim complex
(green:yellow) and the Mcl-1:Bim complex (2PQK) (brown:blue). See
text for description.
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these latter residues are highly conserved in other anti-apopto-
tic Bcl-2 proteins, we suggest that this region is labeled the h5
patch. The part of the pocket lined by helix a4 and a5 hasseveral polar interactions similar to those in other Bcl-2
proteins. The most notable is the conserved Arg88 of the
WGR motif in BH1, which interacts with the strictly conserved
Asp157 of Bim. A characteristic feature of the Bﬂ-1 BH3-bind-
ing groove is the higher negative charge in its central region,
contributed by Glu78 and Glu80 at the end of helix a4
(Fig. 2A).
3.3. Comparison of Bim binding in human Bﬂ-1 and Mcl-1
Comparison of the human Bﬂ-1:Bim and human Mcl-1:Bim
(2PQK) [13] complexes does, for the ﬁrst time, allow the
analysis of the binding of the same pro-apoptotic peptide into
two diﬀerent human anti-apoptotic proteins. The comparison
reveals very similar overall peptide backbone conformation
and shows that most of the polar side chains in the two Bim
peptide structures have similar conformations. However, large
diﬀerences are seen in the conformations of the hydrophobic
side chains of the Bim peptide, particularly notable for the
residues Trp147, Ile155 and Phe159 of Bim (Fig. 3). The induc-
tion of diﬀerent conformations in the Bim peptide by the two
proteins is likely caused by the speciﬁc topology of the hydro-
phobic patches in Bﬂ-1 and Mcl-1.4. Discussion
The aﬃnities of anti-apoptotic Bcl-2 family members for
BH3-only protein derived peptides has been measured by
M.D. Herman et al. / FEBS Letters 582 (2008) 3590–3594 3593several groups [5–7,15]. Although these studies yield somewhat
diﬀerent quantitative results due to the use of diﬀerent samples
and methodologies, they indicate that the qualitative binding
proﬁles of Bcl-2, Bcl-w and Bcl-xL for BH3-only proteins or
BH3 peptides are very similar, whereas Mcl-1 and Bﬂ-1 exhib-
its a distinct pattern, creating a subclass in the anti-apoptotic
family. The most notable diﬀerence in aﬃnity is seen for the
binding of Bmf and Bad peptides to Bﬂ-1 and Mcl-1, which
are 3–4 orders of magnitudes weaker than the binding of these
peptides to Bcl-2, Bcl-xL and Bcl-w [5]. The modeling of these
peptides into the Bﬂ-1 pocket (not shown) does not reveal
obvious steric hindrances or charge repulsions that could ex-
plain these diﬀerences in aﬃnities. It is therefore unlikely that
the lower aﬃnity of the Bad and Bmf peptide can be explained
by single amino acid substitution and is probably due to coop-
erative eﬀects resulting from several sequence diﬀerences. It is
noteworthy that Bﬂ-1 shows a lower degree of conservation of
residues in the BH3 motif, encompassing helices a2 and a3, as
compared to other Bcl-2 proteins (Fig. S1). This might contrib-
ute to the structural diﬀerences seen in helices a2 and a3 and is
likely to be an important determinant for the Bﬂ-1 peptide-
binding selectivity. It has previously been shown that diﬀerent
BH3 peptides have diﬀerent helical propensities [3,9]. The
binding energies are therefore likely to also be dependent on
how well the Bcl-2 proteins are able to enhance these propen-
sities, which is not easily derived from the available structural
data.
The binding aﬃnities of Bim-BH3 to Bﬂ-1 and Mcl-1 are,
however, very similar, in spite of the diﬀerences in the detailed
binding of the Bim peptide to the two proteins. The polar
interactions are likely to confer selectivity and help in orienting
the peptide, where the conserved Asp157:Bim-Arg88:Bﬂ-1 salt
bridge plays a key role. The hydrophobic interactions contrib-
uted by h1–h5 probably play a major role in determining the
aﬃnity of the Bim peptides. The similarity in binding aﬃnities
can be explained by a similar extent of burial of the hydropho-
bic side chains in the two complexes, since the major determi-
nant for the binding energy is likely to be the hydrophobic
eﬀect [22].
Bﬂ-1 activity is regulated by post-translational modiﬁcation
such as phosphorylation and ubiquitinylation at the C-termi-
nal region, or proteolytic removal of the N-terminal BH4 motif
by l-calpain [23]. These modiﬁcations allow Bﬂ-1 to act as an
anti- or pro-apoptotic protein depending on the apoptotic
stimuli. The C-terminal region of Bﬂ-1 is proposed to form
an amphipathic helix that interacts with mitochondrial mem-
branes [24,25], although this is still a matter of debate [26].
All other multidomain Bcl-2 family members have hydropho-
bic C-terminal segments that are suggested to form transmem-
brane helices [3]. The C-terminal helix of Bax binds in a pocket
corresponding to the BH3-intreacting groove [27]. Similarly,
half of the hydrophobic C-terminus of Bcl-w is found in the
peptide-binding pocket, and was shown to interfere with
BH3-only protein interaction [28]. In the Bﬂ-1 structure, the
C-terminus ends close to the Bim binding pocket and it is pos-
sible that the C-terminal helix could insert into the pocket in a
similar manner as in Bcl-w. Post-translational modiﬁcations of
the C-terminal region could be a means to modify its aﬃnity
for the pocket, making it available for BH3-only proteins.
Extensive eﬀorts are being put into developing Bcl-2 inhibi-
tors to be used in cancer therapies [4]. ABT-737 is such an
inhibitor, modeled on the Bad BH3 peptide, which have beenextensively studied and which binds to Bcl-2, Bcl-w and
Bcl-xL, but not Mcl-1 and Bﬂ-1 [29,30]. Superposition of the
Bcl-xL:ABT-737 complex onto the Bﬂ-1 structure (Fig. S2)
reveals sterical hindrance for the chloro-biphenyl and sulphoa-
mide groups of ABT-737, which could explain the low aﬃnity
for Bﬂ-1. Future design will be focused on both member-
speciﬁc and family-wide inhibitors that allow several anti-
apoptotic signals to be blocked simultaneously. The comple-
tion of the structural gallery of anti-apoptotic Bcl-2 family
proteins now allows for the evaluation of the diﬀerent regions
of the binding pockets to aid the design of such family-wide
inhibitors. To achieve this broader speciﬁcity, a possible strat-
egy is to mimic the action of BH3-only peptides hitting on all
anti-apoptotic Bcl-2 proteins, such as Bim and Bid. This might
involve introduction of some of the ﬂexibility seen in the Bim
peptide, allowing the compounds to adjust for local diﬀerences
in the BH3-binding groove.
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